Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Scientists Discover the Gene Behind Age-Related Muscle Loss, Revealing How Exercise Restores Strength
    7 July 2026

    Scientists Discover the Gene Behind Age-Related Muscle Loss, Revealing How Exercise Restores Strength

    Researchers have uncovered a key biological mechanism that explains why muscles become weaker with age and why regular exercise remains one of the most effective ways to preserve muscle strength. The findings identify a gene called DEAF1 as a major driver of age-related muscle decline and suggest it could become a promising target for future therapies.

  • Vertex's CRISPR Gene Therapy CASGEVY Wins FDA Approval for Children as Young as 2 Years
    7 July 2026
    Vertex's CRISPR Gene Therapy CASGEVY Wins FDA Approval for Children as Young as 2 Years

    Vertex Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of CASGEVY (exagamglogene autotemcel), allowing its use in children 2 years of age and older with sickle cell disease (SCD) experiencing recurrent vaso-occlusive crises (VOCs) and transfusion-dependent beta thalassemia (TDT). The therapy was previously approved only for patients aged 12 years and older.

  • Scientists Discover Cause of High-Risk Diffuse Large B-Cell Lymphoma
    6 July 2026
    Scientists Discover Cause of High-Risk Diffuse Large B-Cell Lymphoma
    Researchers have identified a key biological mechanism responsible for the poor prognosis seen in a subset of patients with diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of lymphoma worldwide. In a new study published in Nature Genetics, an international team led by Goethe University Frankfurt, Universitätsmedizin Frankfurt, the German Cancer Consortium (DKTK), and the Frankfurt Cancer Institute discovered novel molecular features that can distinguish high-risk patients who are unlikely to respond to standard first-line treatment.
  • Glenmark Expands U.S. Injectables Portfolio with Launch of Generic Olanzapine Injection
    6 July 2026
    Glenmark Expands U.S. Injectables Portfolio with Launch of Generic Olanzapine Injection

    Glenmark Pharmaceuticals Inc., USA, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited, has announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial in the United States. The newly launched product is bioequivalent and therapeutically equivalent to Zyprexa® IntraMuscular Injection 10 mg/vial (NDA 021253) marketed by Cheplapharm Registration GmbH.

  • New Blood-Based Biomarkers Could Revolutionize Early Detection of Colorectal Cancer, Study Finds
    6 July 2026
    New Blood-Based Biomarkers Could Revolutionize Early Detection of Colorectal Cancer, Study Finds

    A new scientific review has highlighted the growing potential of liquid biomarkers to transform the early detection, diagnosis, and treatment monitoring of colorectal cancer (CRC), offering a less invasive alternative to traditional screening methods such as colonoscopy.

  • Government Expands licensing Rules to Cover Cell & Gene Therapies, Stem Cell Products and Xenografts
    3 July 2026
    Government Expands licensing Rules to Cover Cell & Gene Therapies, Stem Cell Products and Xenografts

    In a significant move to strengthen the regulation of advanced biological therapies in India, the Ministry of Health and Family Welfare has notified the Drugs (Eighth Amendment) Rules, 2026, expanding the scope of the Central Licence Approving Authority (CLAA) under the Drugs Rules, 1945. Through this amendment, Cell or Stem Cell Derived Products, Gene Therapeutic Products, and Xenografts have been formally included alongside Recombinant DNA (r-DNA) derived drugs within the CLAA licensing framework.

  • Mankind Pharma Partners with Denovo Sciences to Accelerate AI-Driven Drug Discovery and Innovation
    3 July 2026
    Mankind Pharma Partners with Denovo Sciences to Accelerate AI-Driven Drug Discovery and Innovation

    Mankind Pharma has announced a strategic collaboration with Denovo Sciences to strengthen its drug discovery capabilities through artificial intelligence (AI), marking a significant step toward technology-enabled pharmaceutical research. The partnership aims to accelerate the identification of promising drug candidates while reducing the time and cost associated with early-stage drug development.

  • Lonza to Expand HPAPI Manufacturing Capacity in Switzerland to Meet Rising ADC Demand
    2 July 2026
    Lonza to Expand HPAPI Manufacturing Capacity in Switzerland to Meet Rising ADC Demand

    Global contract development and manufacturing organization (CDMO) Lonza has announced a major expansion of its highly potent active pharmaceutical ingredient (HPAPI) and payload-linker manufacturing capabilities at its Visp, Switzerland facility. The investment aims to strengthen the company's integrated support for the rapidly growing antibody-drug conjugate (ADC) market.

  • Glenmark Expands Phase 3 Study of Trastuzumab Rezetecan
    2 July 2026
    Glenmark Expands Phase 3 Study of Trastuzumab Rezetecan

    Glenmark Specialty S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark) announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody drug conjugate (ADC), for patients with platinum-resistant ovarian cancer (PROC).

  • Scientists Transform Human Cells into Living Biocomputers, Opening New Path for Precision Cancer Therapy
    1 July 2026
    Scientists Transform Human Cells into Living Biocomputers, Opening New Path for Precision Cancer Therapy
    Researchers at the Hebrew University of Jerusalem have developed an innovative genetic programming system that enables human cells to process information and make autonomous decisions, functioning much like miniature biological computers.
Subscribe to Pharma News